Wogonin promotes cholesterol efflux by increasing protein phosphatase 2B-dependent dephosphorylation at ATP-binding cassette transporter-A1 in macrophages

Journal of Nutritional Biochemistry

Volumn 22, Issue 11, 2011, Pages 1015-1021

  Chen, Chien Yu ^a   Shyue, Song Kun ^b   Ching, Li Chieh ^a   Su, Kuo Hui ^a   Wu, Yu Lin ^a   Kou, Yu Ru ^a,c   Chiang, An Na ^a   Pan, Ching Chian ^a   Lee, Tzong Shyuan ^a,b  

^a NATIONAL YANG MING UNIVERSITY   (Taiwan)

^b INSTITUTE OF BIOMEDICAL SCIENCES   (Taiwan)

^c CHINA MEDICAL UNIVERSITY   (Taiwan)

Author keywords

ATP binding cassette transporter A1; Foam cell; Protein phosphatase 2B; Wogonin

Indexed keywords

4,4' DIISOTHIOCYANATOSTILBENE 2,2' DISULFONIC ACID; ABC TRANSPORTER A1; ABC TRANSPORTER G1; CALCINEURIN; CD36 ANTIGEN; CHOLESTEROL; MESSENGER RNA; NEUTRALIZING ANTIBODY; OXIDIZED LOW DENSITY LIPOPROTEIN; SCAVENGER RECEPTOR A; SCAVENGER RECEPTOR BI; WOGONIN;

ANIMAL CELL; ARTICLE; ATHEROSCLEROSIS; CHOLESTEROL METABOLISM; LIPID STORAGE; MACROPHAGE; NONHUMAN; PROTEIN DEGRADATION; PROTEIN DEPHOSPHORYLATION; PROTEIN EXPRESSION; PROTEIN STABILITY; UPREGULATION;

4,4'-DIISOTHIOCYANOSTILBENE-2,2'-DISULFONIC ACID; ANIMALS; ATP-BINDING CASSETTE TRANSPORTERS; CALCINEURIN; CELLS, CULTURED; CHOLESTEROL; FLAVANONES; FOAM CELLS; LIPOPROTEINS; LIPOPROTEINS, LDL; MACROPHAGES; MICE; SCAVENGER RECEPTORS, CLASS A; SCAVENGER RECEPTORS, CLASS B;

MURINAE; SCUTELLARIA BAICALENSIS;

EID: 80054067148     PISSN: 09552863     EISSN: 18734847     Source Type: Journal    
DOI: 10.1016/j.jnutbio.2010.08.014     Document Type: Article

References (52)

1. Berliner J.A., Heinecke J.W. The role of oxidized lipoproteins in atherogenesis. Free Radic Biol Med 1996, 20:707-727.
2. Glass C.K., Witztum J.L. Atherosclerosis. the road ahead. Cell 2001, 104:503-516.
3. Lusis A.J. Atherosclerosis. Nature 2000, 407:233-241.
4. Li A.C., Glass C.K. The macrophage foam cell as a target for therapeutic intervention. Nat Med 2002, 8:1235-1242.
5. Kunjathoor V.V., Febbraio M., Podrez E.A., Moore K.J., Andersson L., Koehn S., et al. Scavenger receptors class A-I/II and CD36 are the principal receptors responsible for the uptake of modified low density lipoprotein leading to lipid loading in macrophages. J Biol Chem 2002, 277:49982-49988.
6. Rahaman S.O., Lennon D.J., Febbraio M., Podrez E.A., Hazen S.L., Silverstein R.L. A CD36-dependent signaling cascade is necessary for macrophage foam cell formation. Cell Metab 2006, 4:211-221.
7. Witztum J.L. You are right too!. J Clin Invest 2005, 115:2072-2075.
8. Van Eck M., Bos I.S., Hildebrand R.B., Van Rij B.T., Van Berkel T.J. Dual role for scavenger receptor class B, type I on bone marrow-derived cells in atherosclerotic lesion development. Am J Pathol 2004, 165:785-794.
9. Joyce C.W., Amar M.J., Lambert G., Vaisman B.L., Paigen B., Najib-Fruchart J., et al. The ATP binding cassette transporter A1 (ABCA1) modulates the development of aortic atherosclerosis in C57BL/6 and apoE-knockout mice. Proc Natl Acad Sci U S A 2002, 99:407-412.
10. Out R., Hoekstra M., Hildebrand R.B., Kruit J.K., Meurs I., Li Z., et al. Macrophage ABCG1 deletion disrupts lipid homeostasis in alveolar macrophages and moderately influences atherosclerotic lesion development in LDL receptor-deficient mice. Arterioscler Thromb Vasc Biol 2006, 26:2295-2300.
11. Hayek T., Fuhrman B., Vaya J., Rosenblat M., Belinky P., Coleman R., et al. Reduced progression of atherosclerosis in apolipoprotein E-deficient mice following consumption of red wine, or its polyphenols quercetin or catechin, is associated with reduced susceptibility of LDL to oxidation and aggregation. Arterioscler Thromb Vasc Biol 1997, 17:2744-2752.
12. Fuhrman B., Aviram M. Flavonoids protect LDL from oxidation and attenuate atherosclerosis. Curr Opin Lipidol 2001, 12:41-48.
13. Whitman S.C., Kurowska E.M., Manthey J.A., Daugherty A. Nobiletin, a citrus flavonoid isolated from tangerines, selectively inhibits class A scavenger receptor-mediated metabolism of acetylated LDL by mouse macrophages. Atherosclerosis 2005, 178:25-32.
14. Xia M., Hou M., Zhu H., Ma J., Tang Z., Wang Q., et al. Anthocyanins induce cholesterol efflux from mouse peritoneal macrophages: the role of the peroxisome proliferator-activated receptor γ-liver X receptor α-ABCA1 pathway. J Biol Chem 2005, 280:36792-36801.
15. Tai M.C., Tsang S.Y., Chang L.Y., Xue H. Therapeutic potential of wogonin: a naturally occurring flavonoid. CNS Drug Rev 2005, 11:141-150.
16. Efferth T., Fu Y.J., Zu Y.G., Schwarz G., Konkimalla V.S., Wink M. Molecular target-guided tumor therapy with natural products derived from traditional Chinese medicine. Curr Med Chem 2007, 14:2024-2032.
17. Lin Y., Shi R., Wang X., Shen H.M. Luteolin, a flavonoid with potential for cancer prevention and therapy. Curr Cancer Drug Targets 2008, 8:634-646.
18. Ma Z., Otsuyama K., Liu S., Abroun S., Ishikawa H., Tsuyama N., et al. Baicalein, a component of Scutellaria radix from Huang-Lian-Jie-Du-Tang (HLJDT), leads to suppression of proliferation and induction of apoptosis in human myeloma cells. Blood 2005, 105:3312-3318.
19. Himeji M., Ohtsuki T., Fukazawa H., Tanaka M., Yazaki S., Ui S., et al. Difference of growth-inhibitory effect of Scutellaria baicalensis-producing flavonoid wogonin among human cancer cells and normal diploid cell. Cancer Lett 2007, 245:269-274.
20. Li-Weber M. New therapeutic aspects of flavones: the anticancer properties of Scutellaria and its main active constituents wogonin, baicalein and baicalin. Cancer Treat Rev 2009, 35:57-68.
21. Gao Z., Huang K., Yang X., Xu H. Free radical scavenging and antioxidant activities of flavonoids extracted from the radix of Scutellaria baicalensis Georgi. Biochim Biophys Acta 1999, 1472:643-650.
22. Chang Y.L., Shen J.J., Wung B.S., Cheng J.J., Wang D.L. Chinese herbal remedy wogonin inhibits monocyte chemotactic protein-1 gene expression in human endothelial cells. Mol Pharmacol 2001, 60:507-513.
23. Lee S.O., Jeong Y.J., Yu M.H., Lee J.W., Hwangbo M.H., Kim C.H., et al. Wogonin suppresses TNF-α-induced MMP-9 expression by blocking the NF-κB activation via MAPK signaling pathways in human aortic smooth muscle cells. Biochem Biophys Res Commun 2006, 351:118-125.
24. Hsieh Y.C., Hsieh S.J., Chang Y.S., Hsueh C.M., Hsu S.L. The lipoxygenase inhibitor, baicalein, modulates cell adhesion and migration by up-regulation of integrins and vinculin in rat heart endothelial cells. Br J Pharmacol 2007, 151:1235-1245.
25. Wang L.J., Lee T.S., Lee F.Y., Pai R.C., Chau L.Y. Expression of heme oxygenase-1 in atherosclerotic lesions. Am J Pathol 1998, 152:711-720.
26. Lu K.Y., Ching L.C., Su K.H., Yu Y.B., Kou Y.R., Hsiao S.H., et al. Erythropoietin suppresses the formation of macrophage foam cells: role of liver X receptor α. Circulation 2010, 121:1828-1837.
27. Han K.H., Chang M.K., Boullier A., Green S.R., Li A., Glass C.K., et al. Oxidized LDL reduces monocyte CCR2 expression through pathways involving peroxisome proliferator-activated receptor γ. J. Clin Invest 2000, 106:793-802.
28. Martinez L.O., Agerholm-Larsen B., Wang N., Chen W., Tall A.R. Phosphorylation of a pest sequence in ABCA1 promotes calpain degradation and is reversed by ApoA-I. J Biol Chem 2003, 278:37368-37374.
29. Wang N., Tall A.R. Regulation and mechanisms of ATP-binding cassette transporter A1-mediated cellular cholesterol efflux. Arterioscler Thromb Vasc Biol 2003, 23:1178-1184.
30. Yamauchi Y., Hayashi M., Abe-Dohmae S., Yokoyama S. Apolipoprotein A-I activates protein kinase C α signaling to phosphorylate and stabilize ATP binding cassette transporter A1 for the high density lipoprotein assembly. J Biol Chem 2003, 278:47890-47897.
31. Wang Y., Oram J.F. Unsaturated fatty acids phosphorylate and destabilize ABCA1 through a phospholipase D2 pathway. J Biol Chem 2005, 280:35896-36903.
32. Wang Y., Oram J.F. Unsaturated fatty acids phosphorylate and destabilize ABCA1 through a protein kinase C delta pathway. J Lipid Res 2007, 48:1062-1068.
33. Hu Y.W., Ma X., Li X.X., Liu X.H., Xiao J., Mo Z.C., et al. Eicosapentaenoic acid reduces ABCA1 serine phosphorylation and impairs ABCA1-dependent cholesterol efflux through cyclic AMP/protein kinase A signaling pathway in THP-1 macrophage-derived foam cells. Atherosclerosis 2009, 204:e35-e43.
34. Jin S., Mathis A.S., Rosenblatt J., Minko T., Friedman G.S., Gioia K., et al. Insights into cyclosporine A-induced atherosclerotic risk in transplant recipients: macrophage scavenger receptor regulation. Transplantation 2004, 77:497-504.
35. Le Goff W., Peng D.Q., Settle M., Brubaker G., Morton R.E., Smith J.D., et al. Cyclosporin A traps ABCA1 at the plasma membrane and inhibits ABCA1-mediated lipid efflux to apolipoprotein A-I. Arterioscler Thromb Vasc Biol 2004, 24:2155-2161.
36. Li A.C., Binder C.J., Gutierrez A., Brown K.K., Plotkin C.R., Pattison J.W., et al. Differential inhibition of macrophage foam-cell formation and atherosclerosis in mice by PPARα, β/δ, and γ. J Clin Invest 2004, 114:1564-1576.
37. Zou Y., Lu Y., Wei D. Hypocholesterolemic effects of a flavonoid-rich extract of Hypericum perforatum L. in rats fed a cholesterol-rich diet. J Agric Food Chem 2005, 53:2462-2466.
38. Xu G., Watanabe T., Iso Y., Koba S., Sakai T., Nagashima M., et al. Preventive effects of heregulin-β1 on macrophage foam cell formation and atherosclerosis. Circ Res 2009, 105:500-510.
39. Osto E., Kouroedov A., Mocharla P., Akhmedov A., Besler C., Rohrer L., et al. Inhibition of protein kinase Cβ prevents foam cell formation by reducing scavenger receptor A expression in human macrophages. Circulation 2008, 118:2174-2182.
40. Kao E.S., Tseng T.H., Lee H.J., Chan K.C., Wang C.J. Anthocyanin extracted from Hibiscus attenuate oxidized LDL-mediated foam cell formation involving regulation of CD36 gene. Chem Biol Interact 2009, 179:212-218.
41. Aiello R.J., Brees D., Bourassa P.A., Royer L., Lindsey S., Coskran T., et al. Increased atherosclerosis in hyperlipidemic mice with inactivation of ABCA1 in macrophages. Arterioscler Thromb Vasc Biol 2002, 22:630-637.
42. Van Eck M., Bos I.S., Kaminski W.E., Orso E., Rothe G., Twisk J., et al. Leukocyte ABCA1 controls susceptibility to atherosclerosis and macrophage recruitment into tissues. Proc Natl Acad Sci U S A 2002, 99:6298-6303.
43. Yvan-Charvet L., Ranalletta M., Wang N., Han S., Terasaka N., Li R., et al. Combined deficiency of ABCA1 and ABCG1 promotes foam cell accumulation and accelerates atherosclerosis in mice. J Clin Invest 2007, 117:3900-3908.
44. Terra X., Fernández-Larrea J., Pujadas G., Ardevol A., Blade C., Salvado J., et al. Inhibitory effects of grape seed procyanidins on foam cell formation in vitro. J Agric Food Chem 2009, 57:2588-2594.
45. Berrougui H., Grenier G., Loued S., Drouin G., Khalil A. A new insight into resveratrol as an atheroprotective compound: inhibition of lipid peroxidation and enhancement of cholesterol efflux. Atherosclerosis 2009, 207:420-427.
46. Chinetti G., Lestavel S., Bocher V., Remaley A.T., Neve B., Torra I.P., et al. PPAR-α and PPAR-γ activators induce cholesterol removal from human macrophage foam cells through stimulation of the ABCA1 pathway. Nat Med 2001, 7:53-58.
47. Arakawa R., Yokoyama S. Helical apolipoproteins stabilize ATP-binding cassette transporter A1 by protecting it from thiol protease-mediated degradation. J Biol Chem 2002, 277:22426-22429.
48. Wang N., Chen W., Linsel-Nitschke P., Martinez L.O., Agerholm-Larsen B., Silver D.L., et al. A PEST sequence in ABCA1 regulates degradation by calpain protease and stabilization of ABCA1 by apoA-I. J Clin Invest 2003, 111:99-107.
49. Arakawa R., Tsujita M., Iwamoto N., Ito-Ohsumi C., Lu R., Wu C.A., et al. Pharmacological inhibition of ABCA1 degradation increases HDL biogenesis and exhibits antiatherogenesis. J Lipid Res 2009, 50:2299-2305.
50. Lee T.S., Lin C.Y., Tsai J.Y., Wu Y.L., Su K.H., Lu K.Y., et al. Resistin increases lipid accumulation by affecting class A scavenger receptor, CD36 and ATP-binding cassette transporter-A1 in macrophages. Life Sci 2009, 84:97-104.
51. Chueh S.C., Kahan B.D. Dyslipidemia in renal transplant recipients treated with a sirolimus and cyclosporine-based immunosuppressive regimen: incidence, risk factors, progression, and prognosis. Transplantation 2003, 76:375-382.
52. Jardine A.G. Assessing the relative risk of cardiovascular disease among renal transplant patients receiving tacrolimus or cyclosporine. Transpl Int 2005, 18:379-384.